{
    "nct_id": "NCT06440850",
    "official_title": "A Pilot Clinical Trial of Vemurafenib and Cobimetinib as a Redifferentiation Strategy in High-Risk, Radioactive Iodine (RAI) Naïve, BRAFV600E Mutated Differentiated Thyroid Carcinoma Patients Undergoing Initial RAI Therapy",
    "inclusion_criteria": "* Documented informed consent of the participant and/or legally authorized representative\n* Willingness to be followed for about 14 months\n* Males or females aged ≥ 18 years at the time of informed consent\n* Patients with thyroid carcinoma of follicular origin (papillary, follicular or Hurthle cell)\n* Known positive BRAFV600E mutation (determined on a previous analysis and/or on a representative formalin-fixed paraffin embedded (FFPE) tumor samples or on a biopsy sample)\n* High risk for recurrence according to the American Thyroid Association (ATA) guideline defined as having one or more of the features below:\n\n  * Gross extrathyroidal extension\n  * FTC with extensive vascular invasion (> 4), although less likely to have BRAF mutation\n  * PTC with vascular invasion\n  * Advanced nodal disease of (any node >3 cm, > 4 nodes, or extra-nodal extension)\n  * BRAF+TERT promoter mutation\n  * Post op thyroglobulin (TG) suggestive of distant metastasis\n  * Distant metastatic sites (only for exploratory arm)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n* Blood pressure (BP) ≤ 140/90 mm Hg at screening with or without antihypertensive medications and no change in antihypertensive medications within 1 week prior to treatment start\n* Creatinine clearance ≥ 50 mL/min according to the Cockcroft and Gault formula\n* Absolute neutrophil count (ANC) ≥ 1.5 x 109/L\n* Hemoglobin ≥ 9.0 g/dL\n* Platelet count ≥ 100 x 109/L\n* Normal blood coagulation function as evidenced by an International Normalized Ratio (INR) ≤ 1.5\n* Bilirubin ≤ 1.5 × upper limit of normal (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndrome\n* Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN if subject has liver metastases)\n* Women of childbearing potential must have a negative urine or serum β-HCG pregnancy test within 7 days prior to the administration of the first study treatment\n* Agreement by women of childbearing potential (WOCBP) and males of childbearing potential* to use an effective** method of birth control** for at least 3 months prior to screening through 1 year of study follow-up.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\n\n    * Effective birth control defined as hormonal and/or barrier contraception\n* Non-English speaking persons and adults lacking capacity to consent are not excluded from participation\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior RAI treatment\n* Prior anti-BRAF, anti-MEK treatment such as sorafenib, dabrafenib, vemurafenib, encorafenib, binimetinib, cobimetinib, trametinib, d selumitinib and other TKIs like, lenvatinib, sunitinib, axitinib, cabozantenib, vandatinib, pazopanib use\n* Low to intermediate risk differentiated thyroid cancer (DTC) cases (not having the high-risk features as described above)\n* RAI contraindication\n* Undifferentiated or Medullary (MTC) carcinoma of the thyroid\n* Major surgery within 4 weeks prior to the first dose of treatment\n* Subjects having > 1 + proteinuria on urine dipstick testing will undergo 24 h urine collection for quantitative assessment of proteinuria. Subjects with urine protein ≥ 1 g/24 h will be ineligible\n* Need for locoregional treatment such as surgery, external beam radiation or thermoablation at inclusion\n* External beam radiation, for thyroid cancer, <4 weeks prior initiation of treatment\n* Gastrointestinal malabsorption or any other condition that in the opinion of the investigator might affect the absorption of the drugs\n* History of congestive heart failure greater or equal to than New York Heart association (NYHA) Class II, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of treatment, or cardiac arrhythmia associated with significant cardiovascular impairment and uncontrolled hypertension\n* Electrocardiogram (ECG) with QT interval (QTc) interval ≥ 480 msec\n* Active hemoptysis (bright red blood of at least 0.5 teaspoon) within 2 months prior to the first dose of treatment and any other active bleeding, coagulopathy or pathologic condition that would confer a high risk of bleeding\n* Active infection requiring systemic therapy\n* Active malignancy (except for DTC, or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or bladder) within the past 24 months\n* Any history of or concomitant medical condition that, in the opinion of the investigator, would compromise subject's ability to safely complete the protocol\n* Females who are pregnant or breastfeeding\n* Patients with an injection of radio-contrast agent within 12 weeks prior to enrollment (can be enrolled after 12 weeks)\n* Previous history of retinal vein occlusion\n* Previous history of central serious retinopathy\n* Known hypersensitivity to the study drugs or to any of the excipients\n* Any other condition (including psychosocial condition) that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Any other condition that would confound study results\n* Noncompliance\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
    "miscellaneous_criteria": ""
}